Zentalis Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Julia Marie Eastland
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10275 Science Center Drive San Diego CA United States of America 92121
- IPO Date
- Apr 3, 2020
- CIK
- 0001725160
- Website
- zentalis.com
- Similar Companies
- Business
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer, with a primary focus on its lead candidate azenosertib (ZN-c3), a potentially first-in-class and best-in-class oral WEE1 inhibitor for advanced solid tumors including Cyclin E1-positive platinum-resistant ovarian cancer (PROC), uterine serous carcinoma (USC), PARP-resistant ovarian cancer, osteosarcoma, and BRAF V600E-mutated colorectal cancer; the company conducts ongoing Phase 2 monotherapy trials such as DENALI and TETON, Phase 1/2 combination studies with chemotherapy, PARP inhibitors, gemcitabine, and partners' agents like Pfizer's encorafenib and cetuximab, alongside a Phase 1 dose optimization study in solid tumors. Founded in 2014 and headquartered in San Diego, California, Zentalis operates primarily in the United States with a global clinical trial footprint targeting oncology patients in high-unmet-need segments. Recent developments include dosing the first patient in DENALI Part 2 registration-intent trial in April 2025 for Cyclin E1+ PROC with topline data anticipated by year-end 2026 and potential accelerated approval pathway, completion of TETON Phase 2 enrollment in USC with data planned for first-half 2026 amid prioritization of PROC, positive interim DENALI Part 1b data showing 34.9% objective response rate and 6.3-month median duration of response as of January 2025, a 2024 FDA partial clinical hold resolution on key azenosertib studies following sepsis cases, strategic leadership changes with CEO Julie Eastland and new CLO James Bucher appointed in 2025, and a cash position of $280.7 million as of Q3 2025 supporting operations into late 2027.
Company News
BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer